Molecular targets and mechanisms of radiosensitization using DNA damage response pathways

Future Oncology

Volumn 9, Issue 2, 2013, Pages 219-233

  Raleigh, David R ^a   Haas Kogan, Daphne A ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

apoptosis; cell cycle; DNA damage response; ionizing radiation; radioprotection; radiosensitization

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; 2,6 DIAMINO 4 CYCLOHEXYLMETHOXY 5 NITROSOPYRIMIDINE; 4 DIALLYLAMINOMETHYLENE 1,3,4,7,10,11,12,13,14,15,16,17 DODECAHYDRO 6 HYDROXY 1 METHOXYMETHYL 10,13 DIMETHYL 3,7,17 TRIOXO 2 OXACYCLOPENTA[A]PHENANTHREN 11 YL ACETATE; 5 (3 FLUOROPHENYL) N (3 PIPERIDINYL) 3 UREIDO 2 THIOPHENECARBOXAMIDE; ANTINEOPLASTIC AGENT; ATM PROTEIN; CARBOPLATIN; CASPASE 2; CCT 241533; CHECKPOINT KINASE 2; CISPLATIN; HYDROXYUREA; KU 60019; PV 1019; RADIOSENSITIZING AGENT; UNCLASSIFIED DRUG; VRX 0466617; WORTMANNIN;

ANTINEOPLASTIC ACTIVITY; CANCER MODEL; CANCER RADIOTHERAPY; CELL CYCLE ARREST; DNA DAMAGE; GENE MUTATION; GENOMIC INSTABILITY; HUMAN; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN TARGETING; RADIOSENSITIVITY; RADIOSENSITIZATION; REVIEW; SIGNAL TRANSDUCTION; SOLID TUMOR;

ANIMALS; DNA DAMAGE; HUMANS; RADIATION TOLERANCE; RADIATION-SENSITIZING AGENTS; SIGNAL TRANSDUCTION;

EID: 84874050842     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.12.185     Document Type: Review

References (154)

1. Ward JF. The yield of DNA double-strand breaks produced intracellularly by ionizing radiation: A review. Int. J. Radiat. Biol. 57(6), 1141-1150 (1990).
2. Nikjoo H, O'Neill P, Wilson WE, Goodhead DT. Computational approach for determining the spectrum of DNA damage induced by ionizing radiation. Radiat. Res. 156(5 Pt 2), 577-583 (2001).
3. Ward JF. The complexity of DNA damage: relevance to biological consequences. Int. J. Radiat. Biol. 66(5), 427-432 (1994).
4. Ward JF. DNA damage produced by ionizing radiation in mammalian cells: identities, mechanisms of formation, and reparability. Prog. Nucleic Acid Res. Mol. Biol. 35, 95-125 (1988).
5. Olive PL. The role of DNA single-and double-strand breaks in cell killing by ionizing radiation. Radiat. Res. 150(Suppl. 5), S42-S51 (1998).
6. Hada M, Georgakilas AG. Formation of clustered DNA damage after high-LET irradiation: A review. J Radiat. Res. 49(3), 203-210 (2008).
7. Hanai R, Yazu M, Hieda K. On the experimental distinction between SSBs and DSBs in circular DNA. Int. J. Radiat. Biol. 73(5), 475-479 (1998).
8. Datta K, Jaruga P, Dizdaroglu M, Neumann RD, Winters TA. Molecular analysis of base damage clustering associated with a site-specific radiation-induced DNA double-strand break. Radiat. Res. 166(5), 767-781 (2006).
9. Lord CJ, Garrett MD, Ashworth A. Targeting the double-strand DNA break repair pathway as a therapeutic strategy. Clin. Cancer Res. 12(15), 4463-4468 (2006).
10. Harper JW, Elledge SJ. The DNA damage response: ten years after. Mol. Cell 28(5), 739-745 (2007).
11. Lawson JD, Kahle KT, Ng K, Carter B, Kesari S, Chen CC. DNA damage response and repair: insights into strategies for radiation sensitization. In: Selected Topics in DNA Repair. Chen CC (Ed). InTech, Rijeka, Croatia (2011).
12. Lee JH, Paull TT. ATM activation by DNA double-strand breaks through the Mre11-Rad50-Nbs1 complex. Science 308(5721), 551-554 (2005).
13. Rogakou EP, Pilch DR, Orr AH, Ivanova VS, Bonner WM. DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. J. Biol. Chem. 273(10), 5858-5868 (1998).
14. Huen MSY, Grant R, Manke I et al. RNF8 transduces the DNA-damage signal via histone ubiquitylation and checkpoint protein assembly. Cell 131(5), 901-914 (2007).
15. Doil C, Mailand N, Bekker-Jensen S et al. RNF168 binds and amplifies ubiquitin conjugates on damaged chromosomes to allow accumulation of repair proteins. Cell 136(3), 435-446 (2009).
16. Zou L, Elledge SJ. Sensing DNA damage through ATRIP recognition of RPA-ssDNA complexes. Science 300(5625), 1542-1548 (2003).
17. Goedecke W, Eijpe M, Offenberg HH, Van Aalderen M, Heyting C. Mre11 and Ku70 interact in somatic cells, but are differentially expressed in early meiosis. Nat. Genet. 23(2), 194-198 (1999).
18. Myers JS, Cortez D. Rapid activation of ATR by ionizing radiation requires ATM and Mre11. J. Biol. Chem. 281(14), 9346-9350 (2006).
19. Dinkelmann M, Spehalski E, Stoneham T et al. Multiple functions of MRN in end-joining pathways during isotype class switching. Nat. Struct. Mol. Biol. 16(8), 808-813 (2009).
20. Matsuoka S, Ballif BA, Smogorzewska A et al. ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage. Science 316(5828), 1160-1166 (2007).
21. Abraham RT. Cell cycle checkpoint signaling through the ATM and ATR kinases. Genes Dev. 15(17), 2177-2196 (2001).
22. Guo Z, Kozlov S, Lavin MF, Person MD, Paull TT. ATM activation by oxidative stress. Science 330(6003), 517-521 (2010).
23. Valentin-Vega YA, Kastan MB. A new role for ATM: regulating mitochondrial function and mitophagy. Autophagy 8(5), 840-841 (2012).
24. Waldman T, Kinzler KW, Vogelstein B. p21 is necessary for the p53-mediated G1 arrest in human cancer cells. Cancer Res. 55(22), 5187-5190 (1995).
25. Peters M, Deluca C, Hirao A et al. Chk2 regulates irradiation-induced, p53-mediated apoptosis in Drosophila. Proc. Natl Acad. Sci. USA 99(17), 11305-11310 (2002).
26. Cheng Q, Chen J. Mechanism of p53 stabilization by ATM after DNA damage. Cell Cycle 9(3), 472-478 (2010).
27. Guardavaccaro D, Pagano M. Stabilizers and destabilizers controlling cell cycle oscillators. Mol. Cell 22(1), 1-4 (2006).
28. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 253(5015), 49-53 (1991).
29. Nakayama KI, Nakayama K. Ubiquitin ligases: cell cycle control and cancer. Nat. Rev. Cancer 6(5), 369-381 (2006).
30. Bartek J, Lukas J. DNA damage checkpoints: from initiation to recovery or adaptation. Curr. Opin. Cell Biol. 19(2), 238-245 (2007).
31. Al-Hakim A, Escribano-Diaz C, Landry MC et al. The ubiquitous role of ubiquitin in the DNA damage response. DNA Repair (Amst) 9(12), 1229-1240 (2010).
32. Dou H, Huang C, Van Nguyen T, Lu LS, Yeh ETH. SUMOylation and de-SUMOylation in response to DNA damage. FEBS Lett. 585(18), 2891-2896 (2011).
33. Toledo LI, Murga M, Fernandez-Capetillo O. Targeting ATR and Chk1 kinases for cancer treatment: A new model for new (and old) drugs. Mol. Oncol. 5(4), 368-373 (2011).
34. Zhang S, Yajima H, Huynh H et al. Congenital bone marrow failure in DNA-PKcs mutant mice associated with deficiencies in DNA repair. J. Cell Biol. 193(2), 295-305 (2011).
35. Tse AN, Carvajal R, Schwartz GK. Targeting checkpoint kinase 1 in cancer therapeutics. Clin. Cancer Res. 13(7), 1955-1960 (2007).
36. Stracker TH, Usui T, Petrini JHJ. Taking the time to make important decisions: the checkpoint effector kinases Chk1 and Chk2 and the DNA damage response. DNA Repair (Amst) 8(9), 1047-1054 (2009).
37. Bartek J, Lukas J. Chk1 and Chk2 kinases in checkpoint control and cancer. Cancer Cell 3(5), 421-429 (2003).
38. Madoz-Gúrpide J, Cañamero M, Sanchez L, Solano J, Alfonso P, Casal Ji. A proteomics analysis of cell signaling alterations in colorectal cancer. Mol. Cell. Proteomics 6(12), 2150-2164 (2007).
39. Verlinden L, Vanden Bempt I, Eelen G et al. The E2F-regulated gene Chk1 is highly expressed in triple-negative estrogen receptor/progesterone receptor/HER2 breast carcinomas. Cancer Res. 67(14), 6574-6581 (2007).
40. Bao S, Wu Q, Mclendon Re et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444(7120), 756-760 (2006).
41. Buck D, Malivert L, De Chasseval R et al. Cernunnos, a novel nonhomologous endjoining factor, is mutated in human immunodeficiency with microcephaly. Cell 124(2), 287-299 (2006).
42. Gatti RA. The inherited basis of human radiosensitivity. Acta Oncol. 40(6), 702-711 (2001).
43. German J, Sanz MM, Ciocci S, Ye TZ, Ellis NA. Syndrome-causing mutations of the BLM gene in persons in the Bloom's Syndrome Registry. Hum. Mutat. 28(8), 743-753 (2007).
44. Kastan MB, Bartek J. Cell cycle checkpoints and cancer. Nature 432(7015), 316-323 (2004).
45. Moshous D, Li L, Chasseval R et al. A new gene involved in DNA double-strand break repair and V(D)J recombination is located on human chromosome 10p. Hum. Mol. Genet. 9(4), 583-588 (2000).
46. Nance MA, Berry SA. Cockayne syndrome: review of 140 cases. Am. J. Med. Genet. 42(1), 68-84 (1992).
47. O'Driscoll M, Gennery AR, Seidel J, Concannon P, Jeggo PA. An overview of three new disorders associated with genetic instability: LIG4 syndrome, RSSCID and ATRSeckel syndrome. DNA Repair (Amst) 3(8-9), 1227-1235 (2004).
48. Pollard JM, Gatti RA. Clinical radiation sensitivity with DNA repair disorders: an overview. Int. J. Radiat. Oncol. Biol. Phys. 74(5), 1323-1331 (2009).
49. Taylor AMR, Groom A, Byrd PJ. Ataxia-telangiectasia-like disorder (ATLD)-its clinical presentation and molecular basis. DNA Repair (Amst) 3(8-9), 1219-1225 (2004).
50. Winkelstein JA, Marino MC, Lederman HM et al. Xlinked agammaglobulinemia: report on a United States registry of 201 patients. Medicine (Baltimore) 85(4), 193-202 (2006).
51. Rotman G, Shiloh Y. ATM: from gene to function. Hum. Mol. Genet. 7(10), 1555-1563 (1998).
52. Morgan SE, Kastan MB. p53 and ATM: cell cycle, cell death, and cancer. Adv. Cancer Res. 71, 1-25 (1997).
53. Reiman A, Srinivasan V, Barone G et al. Lymphoid tumours and breast cancer in ataxia telangiectasia; substantial protective effect of residual ATM kinase activity against childhood tumours. Br. J. Cancer. 105(4), 586-591 (2011).
54. Thompson D, Duedal S, Kirner J et al. Cancer risks and mortality in heterozygous ATM mutation carriers. J. Natl Cancer Inst. 97(11), 813-822 (2005).
55. Renwick A, Thompson D, Seal S et al. ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles. Nat. Genet. 38(8), 873-875 (2006).
56. Barlow C, Hirotsune S, Paylor R et al. Atm-deficient mice: A paradigm of ataxia telangiectasia. Cell 86(1), 159-171 (1996).
57. Xu Y, Ashley T, Brainerd EE, Bronson RT, Meyn MS, Baltimore D. Targeted disruption of ATM leads to growth retardation, chromosomal fragmentation during meiosis, immune defects, and thymic lymphoma. Genes Dev. 10(19), 2411-2422 (1996).
58. Yamamoto K, Wang Y, Jiang W et al. Kinase-dead ATM protein causes genomic instability and early embryonic lethality in mice. J. Cell Biol. 198(3), 305-313 (2012).
59. Daniel JA, Pellegrini M, Lee BS et al. Loss of ATM kinase activity leads to embryonic lethality in mice. J. Cell Biol. 198(3), 295-304 (2012).
60. Ben-Hur E, Elkind MM, Bronk BV. Thermally enhanced radioresponse of cultured Chinese hamster cells: inhibition of repair of sublethal damage and enhancement of lethal damage. Radiat. Res. 58(1), 38-51 (1974).
61. Dewey WC, Hopwood LE, Sapareto SA, Gerweck LE. Cellular responses to combinations of hyperthermia and radiation. Radiology 123(2), 463-474 (1977).
62. Corry PM, Robinson S, Getz S. Hyperthermic effects on DNA repair mechanisms. Radiology 123(2), 475-482 (1977).
63. Pandita TK, Pandita S, Bhaumik SR. Molecular parameters of hyperthermia for radiosensitization. Crit. Rev. Eukaryot. Gene Expr. 19(3), 235-251 (2009).
64. van der Zee J. Heating the patient: A promising approach? Ann. Oncol. 13(8), 1173-1184 (2002).
65. Matsumoto Y, Suzuki N, Sakai K, Morimatsu A, Hirano K, Murofushi H. A possible mechanism for hyperthermic radiosensitization mediated through hyperthermic lability of Ku subunits in DNAdependent protein kinase. Biochem. Biophys. Res. Commun. 234(3), 568-572 (1997).
66. Zhu WG, Seno JD, Beck BD, Dynlacht JR. Translocation of MRE11 from the nucleus to the cytoplasm as a mechanism of radiosensitization by heat. Radiat. Res. 156(1), 95-102 (2001).
67. Seno JD, Dynlacht JR. Intracellular redistribution and modification of proteins of the Mre11/Rad50/Nbs1 DNA repair complex following irradiation and heat-shock. J. Cell. Physiol. 199(2), 157-170 (2004).
68. Gerashchenko BI, Gooding G, Dynlacht JR. Hyperthermia alters the interaction of proteins of the Mre11 complex in irradiated cells. Cytometry A 77(10), 940-952 (2010).
69. Zeng ZC, Jiang GL, Wang GM, Tang ZY, Curran WJ, Iliakis G. DNA-PKcs subunits in radiosensitization by hyperthermia on hepatocellular carcinoma hepG2 cell line. World J. Gastroenterol. 8(5), 797-803 (2002).
70. Rowley R, Zorch M, Leeper DB. Effect of caffeine on radiation-induced mitotic delay: delayed expression of G2 arrest. Radiat. Res. 97(1), 178-185 (1984).
71. Yao SL, Akhtar AJ, Mckenna KA et al. Selective radiosensitization of p53-deficient cells by caffeine-mediated activation of p34cdc2 kinase. Nat. Med. 2(10), 1140-1143 (1996).
72. Sarkaria JN, Busby EC, Tibbetts RS et al. Inhibition of ATM and ATR kinase activities by the radiosensitizing agent, caffeine. Cancer Research 59(17), 4375-4382 (1999).
73. Price BD, Youmell MB. The phosphatidylinositol 3kinase inhibitor wortmannin sensitizes murine fibroblasts and human tumor cells to radiation and blocks induction of p53 following DNA damage. Cancer Res. 56(2), 246-250 (1996).
74. Sarkaria JN, Tibbetts RS, Busby EC, Kennedy AP, Hill DE, Abraham RT. Inhibition of phosphoinositide 3kinase related kinases by the radiosensitizing agent wortmannin. Cancer Research 58(19), 4375-4382 (1998).
75. Wipf P, Minion DJ, Halter RJ et al. Synthesis and biological evaluation of synthetic viridins derived from C(20)heteroalkylation of the steroidal PI3kinase inhibitor wortmannin. Org. Biomol. Chem. 2(13), 1911-1920 (2004).
76. Ferby IM, Waga I, Sakanaka C, Kume K, Shimizu T. Wortmannin inhibits mitogen-activated protein kinase activation induced by platelet-activating factor in guinea pig neutrophils. J. Biol. Chem. 269(48), 30485-30488 (1994).
77. Vanhaesebroeck B, Leevers SJ, Ahmadi K et al. Synthesis and function of 3phosphorylated inositol lipids. Annu. Rev. Biochem. 70, 535-602 (2001).
78. Liu Y, Jiang N, Wu J, Dai W, Rosenblum JS. Polo-like kinases inhibited by wortmannin. Labeling site and downstream effects. J. Biol. Chem. 282(4), 2505-2511 (2007).
79. Vlahos CJ, Matter WF, Hui KY, Brown RF. A specific inhibitor of phosphatidylinositol 3kinase, 2(4morpholinyl)-8phenyl-4H-1benzopyran-4one (LY294002). J. Biol. Chem. 269(7), 5241-5248 (1994).
80. Rosenzweig KE, Youmell MB, Palayoor ST, Price BD. Radiosensitization of human tumor cells by the phosphatidylinositol3kinase inhibitors wortmannin and LY294002 correlates with inhibition of DNAdependent protein kinase and prolonged G2-M delay. Clin. Cancer Res. 3(7), 1149-1156 (1997).
81. Izzard RA, Jackson SP, Smith GC. Competitive and noncompetitive inhibition of the DNAdependent protein kinase. Cancer Res. 59(11), 2581-2586 (1999).
82. Fuhrman CB, Kilgore J, Lacoursiere YD et al. Radiosensitization of cervical cancer cells via double-strand DNA break repair inhibition. Gynecol. Oncol. 110(1), 93-98 (2008).
83. Stauffer F, Holzer P, García-Echeverría C. Blocking the PI3K/PKB pathway in tumor cells. Curr. Med. Chem. Anticancer Agents 5(5), 449-462 (2005).
84. Fujiwara M, Izuishi K, Sano T et al. Modulating effect of the PI3kinase inhibitor LY294002 on cisplatin in human pancreatic cancer cells. J. Exp. Clin. Cancer Res. 27, 76 (2008).
85. Westfall SD, Skinner MK. Inhibition of phosphatidylinositol 3kinase sensitizes ovarian cancer cells to carboplatin and allows adjunct chemotherapy treatment. Mol. Cancer Ther. 4(11), 1764-1771 (2005).
86. Golding SE, Rosenberg E, Valerie N et al. Improved ATM kinase inhibitor KU60019 radiosensitizes glioma cells, compromises insulin, AKT and ERK prosurvival signaling, and inhibits migration and invasion. Mol. Cancer Ther. 8(10), 2894-2902 (2009).
87. Golding SE, Rosenberg E, Adams BR et al. Dynamic inhibition of ATM kinase provides a strategy for glioblastoma multiforme radiosensitization and growth control. Cell Cycle 11(6), 1167-1173 (2012).
88. Prevo R, Fokas E, Reaper PM et al. The novel ATR inhibitor VE821 increases sensitivity of pancreatic cancer cells to radiation and chemotherapy. Cancer Biol. Ther. 13(11), 1072-1081 (2012).
89. Pires IM, Olcina MM, Anbalagan S et al. Targeting radiation-resistant hypoxic tumour cells through ATR inhibition. Br. J. Cancer. 107(2), 291-299 (2012).
90. Peasland A, Wang LZ, Rowling E et al. Identification and evaluation of a potent novel ATR inhibitor, NU6027, in breast and ovarian cancer cell lines. Br. J. Cancer. 105(3), 372-381 (2011).
91. Koniaras K, Cuddihy AR, Christopoulos H, Hogg A, O'Connell MJ. Inhibition of Chk1dependent G2 DNA damage checkpoint radiosensitizes p53 mutant human cells. Oncogene 20(51), 7453-7463 (2001).
92. Luo Y, Rockow-Magnone SK, Kroeger PE et al. Blocking Chk1 expression induces apoptosis and abrogates the G2 checkpoint mechanism. Neoplasia 3(5), 411-419 (2001).
93. Lord CJ, Ashworth A. The DNA damage response and cancer therapy. Nature 481(7381), 287-294 (2012).
94. Wang Q, Fan S, Eastman A, Worland PJ, Sausville EA, O'Connor PM. UCN01: A potent abrogator of G2 checkpoint function in cancer cells with disrupted p53. J. Natl Cancer Inst. 88(14), 956-965 (1996).
95. Graves PR, Yu L, Schwarz JK et al. The Chk1 protein kinase and the Cdc25C regulatory pathways are targets of the anticancer agent UCN01. J. Biol. Chem. 275(8), 5600-5605 (2000).
96. Sausville EA, Arbuck SG, Messmann R et al. Phase I trial of 72hour continuous infusion UCN01 in patients with refractory neoplasms. J. Clin. Oncol. 19(8), 2319-2333 (2001).
97. Kortmansky J, Shah MA, Kaubisch A et al. Phase I trial of the cyclin-dependent kinase inhibitor and protein kinase C inhibitor 7hydroxystaurosporine in combination with fuorouracil in patients with advanced solid tumors. J. Clin. Oncol. 23(9), 1875-1884 (2005).
98. Lara PN, Mack PC, Synold T et al. The cyclin-dependent kinase inhibitor UCN01 plus cisplatin in advanced solid tumors: A California cancer consortium Phase I pharmacokinetic and molecular correlative trial. Clin. Cancer Res. 11(12), 4444-4450 (2005).
99. Hotte Sj, Oza A, Winquist Ew et al. Phase I trial of UCN01 in combination with topotecan in patients with advanced solid cancers: A Princess Margaret Hospital Phase II Consortium study. Ann. Oncol. 17(2), 334-340 (2006).
100. Sampath D, Cortes J, Estrov Z et al. Pharmacodynamics of cytarabine alone and in combination with 7hydroxystaurosporine (UCN01) in AML blasts in vitro and during a clinical trial. Blood 107(6), 2517-2524 (2006).
101. Syljuåsen RG, Sørensen CS, Nylandsted J, Lukas C, Lukas J, Bartek J. Inhibition of Chk1 by CEP3891 accelerates mitotic nuclear fragmentation in response to ionizing radiation. Cancer Research 64(24), 9035-9040 (2004).
102. Gao Q, Zhou J, Huang X et al. Selective targeting of checkpoint kinase 1 in tumor cells with a novel potent oncolytic adenovirus. Mol. Ther. 13(5), 928-937 (2006).
103. Tse AN, Rendahl KG, Sheikh T et al. CHIR124, a novel potent inhibitor of Chk1, potentiates the cytotoxicity of topoisomerase I poisons in vitro and in vivo. Clin. Cancer Res. 13(2 Pt 1), 591-602 (2007).
104. Tao Y, Leteur C, Yang C et al. Radiosensitization by Chir124, a selective CHK1 inhibitor: effects of p53 and cell cycle checkpoints. Cell Cycle 8(8), 1196-1205 (2009).
105. Dai Y, Grant S. New insights into checkpoint kinase 1 in the DNA damage response signaling network. Clin. Cancer Res. 16(2), 376-383 (2010).
106. Zabludoff SD, Deng C, Grondine MR et al. AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies. Mol. Cancer Ther. 7(9), 2955-2966 (2008).
107. Morgan MA, Parsels LA, Zhao L et al. Mechanism of radiosensitization by the Chk1/2 inhibitor AZD7762 involves abrogation of the G2 checkpoint and inhibition of homologous recombinational DNA repair. Cancer Research 70(12), 4972-4981 (2010).
108. Parsels LA, Morgan MA, Tanska DM et al. Gemcitabine sensitization by checkpoint kinase 1 inhibition correlates with inhibition of a Rad51 DNA damage response in pancreatic cancer cells. Mol. Cancer Ther. 8(1), 45-54 (2009).
109. Blasina A, Hallin J, Chen E et al. Breaching the DNA damage checkpoint via PF00477736, a novel small-molecule inhibitor of checkpoint kinase 1. Mol. Cancer Ther. 7(8), 2394-2404 (2008).
110. Matthews DJ, Yakes FM, Chen J et al. Pharmacological abrogation of Sphase checkpoint enhances the anti-tumor activity of gemcitabine in vivo. Cell Cycle 6(1), 104-110 (2007).
111. Sha SK, Sato T, Kobayashi H et al. Cell cycle phenotype-based optimization of G2-abrogating peptides yields CBP501 with a unique mechanism of action at the G2 checkpoint. Mol. Cancer Ther. 6(1), 147-153 (2007).
112. Kohn EA, Yoo CJ, Eastman A. The protein kinase C inhibitor Gö6976 is a potent inhibitor of DNA damage-induced S and G2 cell cycle checkpoints. Cancer Res. 63(1), 31-35 (2003).
113. Arlander SJH, Eapen AK, Vroman BT, Mcdonald RJ, Toft DO, Karnitz LM. Hsp90 inhibition depletes Chk1 and sensitizes tumor cells to replication stress. J. Biol. Chem. 278(52), 52572-52577 (2003).
114. Montano R, Chung I, Garner KM, Parry D, Eastman A. Preclinical development of the novel Chk1 inhibitor SCH900776 in combination with DNAdamaging agents and antimetabolites. Mol. Cancer Ther. 11(2), 427-438 (2012).
115. Collins I, Garrett MD. Targeting the cell division cycle in cancer: CDK and cell cycle checkpoint kinase inhibitors. Curr. Opin. Pharmacol. 5(4), 366-373 (2005).
116. Tao ZF, Lin NH. Chk1 inhibitors for novel cancer treatment. Anticancer Agents Med. Chem. 6(4), 377-388 (2006).
117. Arienti KL, Brunmark A, Axe FU et al. Checkpoint kinase inhibitors: SAR and radioprotective properties of a series of 2arylbenzimidazoles. J. Med. Chem. 48(6), 1873-1885 (2005).
118. Carlessi L, Buscemi G, Larson G, Hong Z, Wu JZ, Delia D. Biochemical and cellular characterization of VRX0466617, a novel and selective inhibitor for the checkpoint kinase Chk2. Mol. Cancer Ther. 6(3), 935-944 (2007).
119. Jobson AG, Lountos GT, Lorenzi PL et al. Cellular inhibition of checkpoint kinase 2 (Chk2) and potentiation of camptothecins and radiation by the novel Chk2 inhibitor PV1019 [7nitro-1Hindole-2carboxylic acid {4[1(guanidinohydrazone)-ethyl]-phenyl}-amide]. J. Pharmacol. Exp. Ther. 331(3), 816-826 (2009).
120. Anderson VE, Walton MI, Eve PD et al. CCT241533 is a potent and selective inhibitor of CHK2 that potentiates the cytotoxicity of PARP inhibitors. Cancer Res. 71(2), 463-472 (2011).
121. Takai H, Naka K, Okada Y et al. Chk2-deficient mice exhibit radioresistance and defective p53-mediated transcription. EMBO J. 21(19), 5195-5205 (2002).
122. Tetsu O, Mccormick F. Proliferation of cancer cells despite CDK2 inhibition. Cancer Cell 3(3), 233-245 (2003).
123. Ortega S, Prieto I, Odajima J et al. Cyclin-dependent kinase 2 is essential for meiosis but not for mitotic cell division in mice. Nat. Genet. 35(1), 25-31 (2003).
124. Senderowicz AM. Novel small molecule cyclin-dependent kinases modulators in human clinical trials. Cancer Biol. Ther. 2(4 Suppl. 1), S84-S95 (2003).
125. Shapiro GI. Cyclin-dependent kinase pathways as targets for cancer treatment. J. Clin. Oncol. 24(11), 1770-1783 (2006).
126. Stathis A, Oza A. Targeting Wee1-like protein kinase to treat cancer. Drug News Perspect. 23(7), 425-429 (2010).
127. Wang Y, Li J, Booher RN et al. Radiosensitization of p53 mutant cells by PD0166285, a novel G(2) checkpoint abrogator. Cancer Res. 61(22), 8211-8217 (2001).
128. Masaki T, Shiratori Y, Rengifo W et al. Cyclins and cyclin-dependent kinases: comparative study of hepatocellular carcinoma versus cirrhosis. Hepatology 37(3), 534-543 (2003).
129. Mir SE, De Witt Hamer PC, Krawczyk PM et al. In silico analysis of kinase expression identifies WEE1 as a gatekeeper against mitotic catastrophe in glioblastoma. Cancer Cell 18(3), 244-257 (2010).
130. Hashimoto O, Shinkawa M, Torimura T et al. Cell cycle regulation by the Wee1 inhibitor PD0166285, pyrido [2,3d] pyimidine, in the B16 mouse melanoma cell line. BMC Cancer 6, 292 (2006).
131. Hirai H, Iwasawa Y, Okada M et al. Small-molecule inhibition of Wee1 kinase by MK1775 selectively sensitizes p53deficient tumor cells to DNA-damaging agents. Mol. Cancer Ther. 8(11), 2992-3000 (2009).
132. Hirai H, Arai T, Okada M et al. MK1775, a small molecule Wee1 inhibitor, enhances anti-tumor efficacy of various DNA-damaging agents, including 5fluorouracil. Cancer Biol. Ther. 9(7), 514-522 (2010).
133. Schellens JH, Leijen S, Shapiro GI et al. A Phase I and pharmacological study of MK1775, a Wee1 tyrosine kinase inhibitor, in both monotherapy and in combination with gemcitabine, cisplatin, or carboplatin in patients with advanced solid tumors. Presented at: 2009 American Society of Clincal Oncology Annual Meeting. Orlando, FL, USA, 29 May-2 June 2009 (Abstract 3510).
134. Mizuarai S, Yamanaka K, Itadani H et al. Discovery of gene expression-based pharmacodynamic biomarker for a p53 context-specific anti-tumor drug Wee1 inhibitor. Mol. Cancer 8, 34 (2009).
135. Kim BY, Kim KA, Kwon O et al. NFkappaB inhibition radiosensitizes KiRas-transformed cells to ionizing radiation. Carcinogenesis 26(8), 1395-1403 (2005).
136. Bristow RG, Benchimol S, Hill RP. The p53 gene as a modifier of intrinsic radiosensitivity: implications for radiotherapy. Radiother. Oncol. 40(3), 197-223 (1996).
137. Wiedemann GJ, Robins HI, Gutsche S et al. Ifosfamide, carboplatin and etoposide (ICE) combined with 41.8 degrees C whole body hyperthermia in patients with refractory sarcoma. Eur. J. Cancer 32A(5), 888-892 (1996).
138. Wu ZH, Miyamoto S. Many faces of NFkappaB signaling induced by genotoxic stress. J. Mol. Med. 85(11), 1187-1202 (2007).
139. Schmitt AM, Crawley CD, Kang S et al. p50 (NFkB1) is an effector protein in the cytotoxic response to DNA methylation damage. Mol. Cell 44(5), 785-796 (2011).
140. Didelot C, Lanneau D, Brunet M et al. Anticancer therapeutic approaches based on intracellular and extracellular heat shock proteins. Curr. Med. Chem. 14(27), 2839-2847 (2007).
141. Tse AN, Sheikh TN, Alan H, Chou TC, Schwartz GK. 90kDa heat shock protein inhibition abrogates the topoisomerase I poison-induced G2/M checkpoint in p53null tumor cells by depleting Chk1 and Wee1. Mol. Pharmacol. 75(1), 124-133 (2009).
142. Dote H, Burgan WE, Camphausen K, Tofilon PJ. Inhibition of Hsp90 compromises the DNA damage response to radiation. Cancer Res. 66(18), 9211-9220 (2006).
143. Camphausen K, Tofilon PJ. Inhibition of Hsp90: A multitarget approach to radiosensitization. Clin. Cancer Res. 13(15 Pt 1), 4326-4330 (2007).
144. Tse AN, Klimstra DS, Gonen M et al. A Phase 1 dose-escalation study of irinotecan in combination with 17allylamino-17demethoxygeldanamycin in patients with solid tumors. Clin. Cancer Res. 14(20), 6704-6711 (2008).
145. Pacey S, Wilson RH, Walton M et al. A Phase I study of the heat shock protein 90 inhibitor alvespimycin (17DMAG) given intravenously to patients with advanced solid tumors. Clin. Cancer Res. 17(6), 1561-1570 (2011).
146. Jia L, Yang J, Hao X et al. Validation of SAG/RBX2/ROC2 E3 ubiquitin ligase as an anticancer and radiosensitizing target. Clin. Cancer Res. 16(3), 814-824 (2010).
147. Jia L, Bickel JS, Wu J et al. RBX1 (RING box protein 1) E3 ubiquitin ligase is required for genomic integrity by modulating DNA replication licensing proteins. J. Biol. Chem. 286(5), 3379-3386 (2011).
148. Jia L, Soengas MS, Sun Y. ROC1/RBX1 E3 ubiquitin ligase silencing suppresses tumor cell growth via sequential induction of G2-M arrest, apoptosis, and senescence. Cancer Res. 69(12), 4974-4982 (2009).
149. Soucy TA, Smith PG, Rolfe M. Targeting NEDD8-activated cullin-RING ligases for the treatment of cancer. Clin. Cancer Res. 15(12), 3912-3916 (2009).
150. Wei D, Li H, Yu J et al. Radiosensitization of human pancreatic cancer cells by MLN4924, an investigational NEDD8-activating enzyme inhibitor. Cancer Research 72(1), 282-293 (2012).
151. Yang D, Tan M, Wang G, Sun Y. The p21dependent radiosensitization of human breast cancer cells by MLN4924, an investigational inhibitor of NEDD8 activating enzyme. PLoS One 7(3), e34079 (2012).
152. Wu ZH, Miyamoto S. Induction of a pro-apoptotic ATM-NFkappaB pathway and its repression by ATR in response to replication stress. EMBO J. 27(14), 1963-1973 (2008).
153. Vance S, Liu E, Zhao L et al. Selective radiosensitization of p53 mutant pancreatic cancer cells by combined inhibition of Chk1 and PARP1. Cell Cycle 10(24), 4321-4329 (2011).
154. Sultana R, Mcneill DR, Abbotts R et al. Synthetic lethal targeting of DNA double-strand break repair deficient cells by human apurinic/apyrimidinic endonuclease inhibitors. Int. J. Cancer 131(10), 2433-2444 (2012).